Calcium homeostasis in neurons is far more central to cognitive development than most clinicians appreciate — and a newly characterized genetic disorder is sharpening that understanding in important ways. Identifying a causal gene for a previously unnamed neurodevelopmental syndrome not only expands the diagnostic map for families affected by autism and intellectual disability, but also illuminates a molecular pathway that could eventually become a therapeutic target.
Researchers characterized de novo variants in NPTN — the gene encoding human neuroplastin (hNp), a transmembrane glycoprotein that functions as an obligate subunit of plasma membrane calcium ATPases (PMCA) — across eight individuals presenting with autism spectrum disorder and mild-to-severe developmental delay or intellectual disability. The variants fell into two functional classes: four affected both hNp55 and hNp65 isoforms, while four others selectively disrupted only hNp65. Two unrelated individuals independently carried the same loss-of-function nonsense variant predicted to cause haploinsufficiency across all isoforms. Haploinsufficient Nptn+/− mice showed measurably reduced neuroplastin and PMCA protein levels alongside altered social behavior. In primary neurons, insufficient neuroplastin expression led to diminished PMCA activity and dysregulated cytosolic calcium transients. Missense variants introduced structural and thermodynamic instabilities in the protein, and in Drosophila, a PMCA-interaction-disrupting missense mutation failed to rescue the lethal phenotype caused by loss of the hNp ortholog.
This work is notable for several reasons beyond gene discovery. PMCA dysfunction as an autism mechanism has been underexplored relative to synaptic scaffolding proteins; this study repositions calcium extrusion capacity as a genuine neurodevelopmental vulnerability. The multi-species validation — mice, Drosophila, human cell lines, and primary neurons — substantially strengthens causal inference, though the cohort of eight individuals remains small. Clinically, the finding argues for including NPTN on neurodevelopmental sequencing panels. Whether PMCA modulators could partially rescue function represents an open and intriguing translational question.